Kristen Farrell

Dr. Kristen Farrell

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2025 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Open access
TMTravis Meuten
Travis Meuten
KFKristen Farrell
Kristen Farrell
BRBarbara J. Rose
Barbara J. Rose
SBSamuel A. Brill
Samuel A. Brill
RBRachel V. Brady
Rachel V. Brady
DTDouglas H. Thamm
Douglas H. Thamm
Canine osteosarcoma (OS) presents a significant clinical challenge in veterinary oncology. Due to the similarities in aggressive biologic behavior, mutation status, and gene expression profiles, the canine patient also provides a spontaneous animal model for OS in humans. Advancements in the treatment of OS have been slow to progress. The phosphatidylinositol 3-kinase (PI3K), AKT serine/threonine kinase (AKT), and mechanistic target of rapamycin (mTOR) signal transduction pathway is implicated in canine and human OS, and presents a potentially valuable therapeutic target. The present study investigated PI3K-AKT-mTOR signaling activity in canine OS cells and the in vitro and in vivo efficacy of a PI3K/mTOR dual inhibitor alone and in combination with cytotoxic chemotherapy drugs for treatment of canine OS. The results of this study demonstrate reduced signal transduction; increased cell death; reduced cell proliferation, migration, invasion, and vascular endothelial growth factor production in vitro; as well as reduced tumor growth and greater survival times with inhibition of PI3K-AKT-mTOR signaling in a xenograft mouse model. We also examined patient-derived tumors for immunoreactivity of forkhead box O1, a downstream target of AKT activation. Unlike the xenograft tumors that were treated with a PI3K/mTOR inhibitor, a correlation between tumor biologic behavior and forkhead box O1 immunoreactivity was not present in the patient-derived tumor sections. These findings indicate both the potential benefits of PI3K/mTOR dual inhibitors in chemotherapeutic protocols and the need for further study of patient-derived tumors to better understand the extent of PI3K-AKT-mTOR activation for the application of such targeted inhibitors. SIGNIFICANCE STATEMENT: The phosphatidylinositol 3-kinase, AKT serine/threonine kinase, and mechanistic target of rapamycin pathway is frequently dysregulated in canine osteosarcoma. VDC597, a dual inhibitor of pathway activation, can potentially improve outcomes of canine osteosarcoma. In vitro, VDC597 inhibited cellular viability, migration, and invasion, vascular endothelial growth factor production, and phosphorylation of signaling proteins, while promoting cell death. In mice treated with VDC597, tumor growth slowed and survival times increased. Effects were found both with VDC597 alone and in combination with other chemotherapy drugs.

16 January 2025 in Molecules
Verified
Journal Article
Open access
PDF file
JKJost Klawitter
Jost Klawitter
MEMckay Easton
Mckay Easton
AKAlexander Karpeisky
Alexander Karpeisky
KFKristen Farrell
Kristen Farrell
DTDouglas H. Thamm
Douglas H. Thamm
SZShawn Patrick Zinnen
Shawn Patrick Zinnen
Background. The use of the bone-seeking properties of bisphosphonates (BPs) to target the delivery of therapeutic drugs is a promising approach for the treatment of bone metastases. Currently, the most advanced example of this approach is a gemcitabine-ibandronate conjugate (GEM-IB), where the bone-targeting BP ibandronate (IB) is covalently linked to the antineoplastic agent gemcitabine (GEM) via a spacer phosphate group. In the present study, we describe the development of a new analytical platform to evaluate the metabolism and pharmacokinetics of GEM-IB in mice and dogs and the results of proof-of-concept studies assessing the pharmacokinetics of GEM-IB in dogs and mice. Methods. We validated analytical platforms to analyze GEM-IB and five of its major metabolites IB, gemcitabine-5′-phosphate (GEMMP), gemcitabine (GEM), 2′,2′-difluoro-2′-deoxyuridine-5′-phosphate (dFdUMP), and 2′,2′-difluoro-2′-deoxyuridine (dFdU) and performed proof-of-concept pharmacokinetic studies in mice (5 mg/kg i.p.) and dogs (5 mg/kg i.v.). Results. Intra- and inter-run accuracy and imprecision (3 days) of the assays met the (FDA) acceptance criteria. The proof-of-concept plasma pharmacokinetic studies in mice showed AUCs of 1278, 10,652, 405, 38, 1063, 3389, and 38 h·ng/mL for GEM-IB, IB, GEMMP, dFdU-MP, GEM, and dFdU, respectively. In dog plasma, AUCs of 295, 5725, 83, 11, 1625, and 6569 h·ng/mL were observed for GEM-IB, IB, GEMMP, dFdUMP, GEM, and dFdU. Conclusions. Pharmacokinetic studies in dogs and mice showed that GEM-IB is rapidly converted to IB and GEM; dFdU is formed (from GEM) with a delay. The rapid disappearance of GEM-IB from circulation could be explained by a combination of metabolism and rapid distribution to tissue/bone.

21 May 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KFKristen Farrell
Kristen Farrell
SDSunetra Das
Sunetra Das
SNSteven K. Nordeen
Steven K. Nordeen
JLJames R. Lambert
James R. Lambert
DTDouglas H. Thamm
Douglas H. Thamm
VDX-111 (also identified as AMPI-109) is a vitamin D derivative which has shown anticancer activity. To further assess the function of this compound against multiple cancer types, we examined the efficacy of VDX-111 against a panel of 30 well characterized canine cancer cell lines. Across a variety of cancer types, VDX-111 induced widely variable growth inhibition, cell death, and migration inhibition, at concentrations ranging from 10 nM to 1 μM. Growth inhibition sensitivity did not correlate strongly with tumor cell histotype; however, it was significantly correlated with the expression of genes in multiple cell signaling pathways, including the MAPK and PI3K-AKT pathways. We confirmed inhibition of these signaling pathways as likely participants in the effects of VDX-111. These results suggest that a subset of canine tumors may be sensitive to treatment with VDX-111, and suggests possible predictive markers of drug sensitivity and pharmacodynamic biomarkers of drug exposure that could be employed in future clinical trials.

22 December 2023 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
LSLisa J. Schlein
Lisa J. Schlein
SBSamuel A. Brill
Samuel A. Brill
RBRachel V. Brady
Rachel V. Brady
KFKristen Farrell
Kristen Farrell
BRBarbara J. Rose
Barbara J. Rose
DTDouglas H. Thamm
Douglas H. Thamm
This study provides a unique translational research opportunity to help both humans and dogs diagnosed with diseases that carry dismal prognoses in both species: histiocytic sarcoma (HS), hemangiosarcoma (HSA), and disseminated mastocytosis/mast cell tumor (MCT).While exceedingly rare in humans, these so called "orphan diseases" are relatively more common in dogs. For these and other, more commonplace cancers like lymphoma (Lym), dogs are an excellent translational model for human disease, due to remarkably similar disease biology. In this study, assays were performed to assess the therapeutic potential of parthenolide (PTL), a known canonical NF-kB signaling inhibitor with additional mechanisms of antineoplastic activity, including alteration of cellular reduction-oxidation balance. Canine cell lines and primary cells are sensitive to PTL and undergo dose-dependent apoptosis following exposure to drug. PTL exposure also leads to glutathione depletion, reactive oxygen species generation, and NF-kB inhibition in canine cells. Standard-of-care therapeutics broadly synergize with PTL. In two canine HS cell lines, expression of NF-kB pathway signaling partners is downregulated with PTL therapy. Preliminary data suggest that PTL inhibits NF-kB activity of cells and extends survival time in a mouse model of disseminated canine HS. These data support further investigation of compounds that can antagonize canonical NF-kB pathway signaling in these cancers and pave the way for clinical trials of PTL in affected dogs. As dogs are an excellent natural disease model for these cancers, these data will ultimately improve our understanding of their human disease counterparts, and hopefully, improve care for both species. Significance Statement Disseminated neoplasms in human and canine cancers are challenging to treat, and novel therapeutic approaches are needed to improve outcomes. PTL is a promising treatment for histiocytic sarcoma (HS), hemangiosarcoma (HSA), and mast cell neoplasia (MCT).

21 April 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KFKristen Farrell
Kristen Farrell
SDSunetra Das
Sunetra Das
DTDouglas H. Thamm
Douglas H. Thamm
Omacetaxine mepesuccinate (OMX), formerly known as homoharringtonine, is a protein translation inhibitor approved for use in human chronic myeloid leukemia. Recent studies suggest that OMX may be effective against other cancer types, and may be successful against protein targets that are otherwise difficult to inhibit by reducing their translation rates. Using canine, human, and mouse osteosarcoma (OS) cell lines, we investigated the antineoplastic effects of OMX against OS by evaluating growth inhibition, migration and invasion, apoptosis, expression of c-Myc, changes in gene expression, and in vivo efficacy. OMX induced dose-dependent growth inhibition and apoptosis of OS cells with IC50 values in the low nanomolar range. OMX also reduced migration and Matrigel invasion. Strikingly, levels of c-Myc protein were reduced in most canine, human, and mouse OS cell lines after OMX exposure, and Myc target RNA transcripts were also reduced with treatment. OMX significantly inhibited tumor growth in and metastasis in two separate orthotopic mouse OS models. OMX is a promising candidate for treatment of OS in both dogs and humans, and potentially other c-Myc-driven cancers.